{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:32:53Z","timestamp":1759159973907},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Several direct-acting agents against the hepatitis C virus (HCV) NS3 protease and NS5b polymerase have been developed in recent years to improve treatment of this viral infection. Of these, simeprevir is currently recommended for HCV genotype 1 and 4 infections, but genotypic assessment for the presence of 80K is required prior to simeprevir administration due to the reduced susceptibility of genotype 1 viruses carrying that polymorphism. Because the prevalence of 80K at baseline in genotype 1 viruses varies between reports, we wanted to assess its worldwide prevalence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Over 3000 HCV genotype 1 sequences reported from drug-naive subjects distributed around the world were retrieved from the HCV Los Alamos and GenBank databases. These were categorized into subtypes and geographical provenance (continent and country), and the presence of the 80K and 80R polymorphisms was visually inspected and counted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Disparate prevalence of 80K was observed depending on the country\/continent analysed. While in resource-rich areas (USA, Western Europe and Australia) a high prevalence of 80K was seen in HCV subtype 1a, in emerging countries, such as Brazil, this prevalence was very low\u00a0(&amp;lt;1%). HCV subtype 1b sequences from France also displayed a significant occurrence of 80K (6.1%). 80R, on the other hand, was negligible worldwide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The genotypic assessment of 80K in HCV subtype 1a prior to simeprevir administration in emerging countries with significant numbers of HCV infection is questionable, while it should be performed for subtype 1b in certain developed countries.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkv081","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T16:36:39Z","timestamp":1428078999000},"page":"2024-2027","source":"Crossref","is-referenced-by-count":8,"title":["Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage"],"prefix":"10.1093","volume":"70","author":[{"given":"Lu\u00e3nna L.","family":"Vidal","sequence":"first","affiliation":[{"name":"1 \u00a0Laborat\u00f3rio de Virologia Humana, Departamento de Gen\u00e9tica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 F.","family":"Santos","sequence":"additional","affiliation":[{"name":"1 \u00a0Laborat\u00f3rio de Virologia Humana, Departamento de Gen\u00e9tica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo A.","family":"Soares","sequence":"additional","affiliation":[{"name":"1 \u00a0Laborat\u00f3rio de Virologia Humana, Departamento de Gen\u00e9tica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"},{"name":"2 \u00a0Programa de Oncovirologia, Instituto Nacional de C\u00e2ncer, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,4,2]]},"reference":[{"issue":"Suppl 1","key":"2022020121025506300_DKV081C1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/liv.12061","article-title":"New therapeutic strategies in HCV: second-generation protease inhibitors","volume":"33","author":"Clark","year":"2013","journal-title":"Liver Int"},{"key":"2022020121025506300_DKV081C2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2012.07.117","article-title":"Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy","volume":"143","author":"Lenz","year":"2012","journal-title":"Gastroenterology"},{"key":"2022020121025506300_DKV081C3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020121025506300_DKV081C4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/AAC.05166-11","article-title":"In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335","volume":"56","author":"Lagac\u00e9","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020121025506300_DKV081C5","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"2022020121025506300_DKV081C6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"2022020121025506300_DKV081C7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"2022020121025506300_DKV081C8","author":"US FDA"},{"key":"2022020121025506300_DKV081C9","author":"EMA"},{"key":"2022020121025506300_DKV081C10","doi-asserted-by":"crossref","first-page":"e34372","DOI":"10.1371\/journal.pone.0034372","article-title":"Hepatitis C viral evolution in genotype 1 treatment-na\u00efve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials","volume":"7","author":"Kieffer","year":"2012","journal-title":"PLoS One"},{"key":"2022020121025506300_DKV081C11","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2873","article-title":"Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype 1 patients with or without HIV coinfection","author":"Lisboa-Neto","year":"2014","journal-title":"Antivir Ther"},{"key":"2022020121025506300_DKV081C12","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/jmv.24015","article-title":"Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches","volume":"86","author":"de Carvalho","year":"2014","journal-title":"J Med Virol"},{"key":"2022020121025506300_DKV081C13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcv.2014.06.023","article-title":"Patients eligible for treatment with simeprevir in a French center","volume":"61","author":"Morel","year":"2014","journal-title":"J Clin Virol"},{"key":"2022020121025506300_DKV081C14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.04.018","article-title":"Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a","volume":"99","author":"Palanisamy","year":"2013","journal-title":"Antiviral Res"},{"key":"2022020121025506300_DKV081C15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1155\/2013\/273856","article-title":"Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir\/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba","volume":"27","author":"Andonov","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"2022020121025506300_DKV081C16","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","article-title":"Clustal W and Clustal X version 2.0","volume":"23","author":"Larkin","year":"2007","journal-title":"Bioinformatics"},{"key":"2022020121025506300_DKV081C17","first-page":"95","article-title":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT","volume":"41","author":"Hall","year":"1999","journal-title":"Nucl Acids Sympos Ser"},{"key":"2022020121025506300_DKV081C18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2334-13-60","article-title":"Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study","volume":"13","author":"Pereira","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2022020121025506300_DKV081C19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antiviral Res"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/7\/2024\/42355096\/jac_70_7_2024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/7\/2024\/42355096\/jac_70_7_2024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T21:19:31Z","timestamp":1643750371000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/7\/2024\/777836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,2]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,4,2]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv081","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,7]]},"published":{"date-parts":[[2015,4,2]]}}}